{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(4)"],"submitter":["Fournier N"],"pubmed_abstract":["Plasmacytoid dendritic cells (pDCs) play a central role for both innate and adaptive antiviral responses, as they direct immune responses through their unique ability to produce substantial concentrations of type I interferon (IFNs) upon viral encounter while also activating multiple immune cells, including macrophages, DCs, B, natural killer and T cells. Recent evidence clearly indicates that pDCs also play a crucial role in some cancers and several auto-immune diseases. Although treatments are currently available to patients with such pathologies, many are not fully efficient. We are proposing here, as a new targeted-based therapy, a novel chimeric monoclonal antibody (mAb) that mediates a strong cellular cytotoxicity directed against a specific human pDC marker, CD303. This antibody, ch"],"journal":["mAbs"],"pagination":["651-663"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5973763"],"repository":["biostudies-literature"],"pubmed_title":["Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern."],"pmcid":["PMC5973763"],"pubmed_authors":["Derache D","Fournier N","Jacque E","Fontayne A","Longue A","Dupont G","Dezetter AS","Baptista L","Dehenne A","Verhaeghe L","Pochet-Beghin V","Chtourou S","Terrier A","Beghin C","de Romeuf C"],"additional_accession":[]},"is_claimable":false,"name":"Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern.","description":"Plasmacytoid dendritic cells (pDCs) play a central role for both innate and adaptive antiviral responses, as they direct immune responses through their unique ability to produce substantial concentrations of type I interferon (IFNs) upon viral encounter while also activating multiple immune cells, including macrophages, DCs, B, natural killer and T cells. Recent evidence clearly indicates that pDCs also play a crucial role in some cancers and several auto-immune diseases. Although treatments are currently available to patients with such pathologies, many are not fully efficient. We are proposing here, as a new targeted-based therapy, a novel chimeric monoclonal antibody (mAb) that mediates a strong cellular cytotoxicity directed against a specific human pDC marker, CD303. This antibody, ch","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 May/Jun","modification":"2025-04-05T15:06:01.769Z","creation":"2019-03-26T23:39:34Z"},"accession":"S-EPMC5973763","cross_references":{"pubmed":["29553870"],"doi":["10.1080/19420862.2018.1451283"]}}